Develops protein therapeutics for neuromuscular diseases.
Jun 2026Revenue $14.5M/yrExpenses $116M/yr
No trendCash runway ≈ 5.3 years from Jun 2026
Figures by year
When will Keros Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $14.5M and expenses $116M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $244M | $176M | $67.6M |
| Dec 2024 | $0.00 | $211M | −$211M |
| Dec 2023 | $151K | $170M | −$170M |
| Dec 2022 | $0.00 | $115M | −$115M |
| Dec 2021 | $20.1M | $76.5M | −$56.4M |
| Dec 2020 | $0.00 | $46.7M | −$46.7M |
| Dec 2019 | $10.0M | $20.6M | −$10.6M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.